SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Short Interest Down 17.6% in December

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was the target of a large drop in short interest in the month of December. As of December 15th, there was short interest totalling 7,460,000 shares, a drop of 17.6% from the November 30th total of 9,050,000 shares. Based on an average trading volume of 978,800 shares, the short-interest ratio is currently 7.6 days.

SELLAS Life Sciences Group Stock Up 1.3 %

SELLAS Life Sciences Group stock traded up $0.01 during midday trading on Monday, hitting $0.99. 834,644 shares of the stock were exchanged, compared to its average volume of 1,115,267. SELLAS Life Sciences Group has a 52 week low of $0.50 and a 52 week high of $1.72. The stock has a market capitalization of $69.90 million, a PE ratio of -1.44 and a beta of 2.39. The company has a fifty day simple moving average of $1.12 and a two-hundred day simple moving average of $1.19.

Hedge Funds Weigh In On SELLAS Life Sciences Group

Several institutional investors and hedge funds have recently made changes to their positions in SLS. Virtu Financial LLC lifted its holdings in shares of SELLAS Life Sciences Group by 24.1% during the 3rd quarter. Virtu Financial LLC now owns 79,241 shares of the company’s stock valued at $99,000 after purchasing an additional 15,398 shares in the last quarter. Geode Capital Management LLC raised its holdings in SELLAS Life Sciences Group by 17.1% during the 3rd quarter. Geode Capital Management LLC now owns 605,191 shares of the company’s stock worth $757,000 after buying an additional 88,183 shares during the period. Anson Funds Management LP bought a new position in SELLAS Life Sciences Group in the third quarter valued at approximately $992,000. XTX Topco Ltd acquired a new position in shares of SELLAS Life Sciences Group in the third quarter valued at approximately $78,000. Finally, State Street Corp boosted its holdings in shares of SELLAS Life Sciences Group by 30.2% in the third quarter. State Street Corp now owns 174,529 shares of the company’s stock valued at $218,000 after buying an additional 40,500 shares during the period. Institutional investors and hedge funds own 17.38% of the company’s stock.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.